Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial
Wu, Yi-Long, Prof, Zhou, Caicun, Prof, Hu, Cheng-Ping, Prof, Feng, Jifeng, Prof, Lu, Shun, Prof, Huang, Yunchao, Prof, Li, Wei, Prof, Hou, Mei, Prof, Shi, Jian Hua, Prof, Lee, Kye Young, Prof, Xu, Chong-Rui, MD, Massey, Dan, MSc, Kim, Miyoung, MD, Shi, Yang, MD, Geater, Sarayut L, MD
Published in The lancet oncology (01.02.2014)
Published in The lancet oncology (01.02.2014)
Get full text
Journal Article
Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials
Yang, James Chih-Hsin, Prof, Wu, Yi-Long, Prof, Schuler, Martin, Prof, Sebastian, Martin, MD, Popat, Sanjay, FRCP, Yamamoto, Nobuyuki, Prof, Zhou, Caicun, Prof, Hu, Cheng-Ping, Prof, O'Byrne, Kenneth, Prof, Feng, Jifeng, Prof, Lu, Shun, Prof, Huang, Yunchao, Prof, Geater, Sarayut L, MD, Lee, Kye Young, Prof, Tsai, Chun-Ming, Prof, Gorbunova, Vera, Prof, Hirsh, Vera, Prof, Bennouna, Jaafar, Prof, Orlov, Sergey, Prof, Mok, Tony, Prof, Boyer, Michael, Prof, Su, Wu-Chou, Prof, Lee, Ki Hyeong, Prof, Kato, Terufumi, MD, Massey, Dan, MSc, Shahidi, Mehdi, MD, Zazulina, Victoria, MD, Sequist, Lecia V, MD
Published in The lancet oncology (01.02.2015)
Published in The lancet oncology (01.02.2015)
Get full text
Journal Article